Perlegen Sciences

Perlegen Sciences
Mountain View, Calif.
Founded: 2001

Why It's Fierce: Perlegen Sciences was spun off from bioarray pioneer Affymetrix to help drug companies quickly identify promising drug targets from volumes of human genome data. The company is mapping 50 human genomes to identify unique genetic variations. Drug companies will use this information to create the first wave of genomics drugs. Pfizer, Eli Lilly, and Bristol-Myers Squibb signed long-term research deals with Perlegen in December, boosting the company's ambitious growth plan.

What to look for in 2003: Perlegen will sign additional partnerships this year, solidifying its leadership position in this emerging niche.

Perlegen Sciences

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.